iShares Biotechnology ETF
IBB
399 hedge funds and large institutions have $6.62B invested in iShares Biotechnology ETF in 2015 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 144 increasing their positions, 113 reducing their positions, and 37 closing their positions.
89% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 37
32% more funds holding in top 10
Funds holding in top 10: 25 → 33 (+8)
27% more repeat investments, than reductions
Existing positions increased: 144 | Existing positions reduced: 113
26% more capital invested
Capital invested by funds: $5.23B → $6.62B (+$1.38B)
8% more funds holding
Funds holding: 369 → 399 (+30)
56% less call options, than puts
Call options by funds: $479M | Put options by funds: $1.09B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$563M |
| 2 |
Goldman Sachs
New York
|
+$279M |
| 3 |
JP Morgan Chase
New York
|
+$199M |
| 4 |
Citigroup
New York
|
+$126M |
| 5 |
Morgan Stanley
New York
|
+$83.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$467M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$137M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$124M |
| 4 |
Barclays
London,
United Kingdom
|
-$98.7M |
| 5 |
Jane Street
New York
|
-$39.6M |
IBB Hedge Fund Activity: Q1 2015 in Review
399 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2015, worth a combined $6.62B — up 26% from $5.23B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new IBB positions and 37 closed out — a net gain of 33 holders — while 144 added to existing stakes and 113 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $563M. The largest seller was Deutsche Bank, exiting entirely with an estimated $467M sold.
- 399 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2015, up from 369 in Q4 2014.
- Funds reported $6.62B of iShares Biotechnology ETF stock for Q1 2015, up 26% quarter-over-quarter.
- 70 funds opened new iShares Biotechnology ETF positions in Q1 2015 and 37 closed out, a net change of +33 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2015 was BNP Paribas Financial Markets, an estimated $563M added.
- The largest iShares Biotechnology ETF seller in Q1 2015 was Deutsche Bank, an estimated $467M sold.
Based on aggregated 13F filings for Q1 2015.